2023-509729-33-00Not yet recruitingPhase 1
A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Jul 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 18 Aug 2025
- Start date
- 1 Aug 2026
- Lead sponsor
- Institut De Cancerologie De L Ouest
- Diseases
- Bladder cancer
- EU CT number
- 2023-509729-33-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 24
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut De Cancerologie De L Ouest | Saint-Herblain Cedex | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.